Premier Biomedical, Inc. announced that it has advanced its pre-clinical testing of its extracorporeal-treatment methodology for use against cancer from test tubes to mice. These tests are being conducted by academic researchers at The University of Texas at El Paso (UTEP) under direction of Dr. Mitchell S. Felder of Premier Biomedical (PBI). PBI and UTEP are ahead of schedule by over one year. Typical laboratory tests take up to 2 years before providing the requisite positive results to move to this next phase of study. However, lab tests have demonstrated the successful removal of picogram (one trillionth of a gram) quantities of cytokines from a heterogeneous mixture. Subsequently, the methodology being tested has had extremely successful laboratory results in the killing of multiple tumors in test tubes that are dependent on these same cytokines for survival. With no anticipated side-effects because of the extracorporeal process, the results could pave the way to the efficacious treatment of cancer treatment in humans. The company indicated that they expect the results from these studies to provide new therapeutic strategies into treating certain forms of cancer during the third quarter of 2013, but other diseases including Alzheimer's Disease and Traumatic Brain Injury are progressing as well. If the results prove successful, use of Premier Biomedical's proprietary technology will be developed further with the goal of initiating clinical studies for these diseases in humans.

Premier Biomedical, Inc. announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier's long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of Premier Biomedical, Inc.'s Felder Doctrine. Retinitis Pigmentosa is a group of inherited disorders characterized by a peripheral vision loss that can eventually lead to central vision loss. RP is most commonly found in isolation, but it can be associated with systemic disease. The most common systemic association is hearing loss, which occurs in up to 30% of patients. There is a great continuing need for treatments for RP.

Premier Biomedical, Inc. announced that effective November 29, 2012, Ramon D. Foltz resigned as a member of its Board of Directors. Mr. Foltz did not hold any position on any committee of Board of Directors.